This Dividend King Just Announced Great News for Investors

Abbott Laboratories reported solid Q3 2026 results with 7% sales growth and 9% higher adjusted EPS. The company announced a significant decision to spin off its struggling nutrition business into a standalone company, which should improve growth prospects. Abbott's core medical device segment, particularly its FreeStyle Libre diabetes care products and recent Exact Sciences acquisition for cancer diagnostics, positions the company well for future growth. As a Dividend King with 50+ consecutive years of dividend increases, Abbott remains attractive for income investors.